Laurie is a member of the Firm’s Corporate Practice Group. She counsels clients across the life sciences and technology industries in a wide range of transactional matters, including venture capital and debt financings, mergers and acquisitions, licensing and strategic collaborations, supply and manufacturing arrangements and capital market transactions. Laurie also serves as trusted outside general counsel to emerging and established private and public companies. In such role, she advises management teams and boards of directors on numerous matters across the corporate lifecycle, including formation and founder issues, corporate governance, structuring matters, research and commercial contracting, and disclosure obligations.
Laurie’s clients include pharmaceutical, medical device, diagnostics, biological materials and tools, AI, and other technology companies. She also represents venture capital firms and hedge funds in connection with their portfolio investments.
Active in the community, Laurie serves as a Lecturer of Law at Boston University School of Law and serves on the boards of directors of Families for Depression Awareness and Girls Inc. of Boston and Lynn. She is also a frequent mentor and speaker for university and incubator programs and maintains active membership in local technology and medical associations, including Women in Bio. Laurie has also received several awards for dedication to pro bono service,
Prior to joining Morse, Laurie was a partner in the corporate business and transactions group at Morgan Lewis & Bockius LLP. Before Morgan Lewis, Laurie was a partner in the technology and life sciences group at Goodwin Procter LLP.
Representative Matters
Private Company Financings *
- A philanthropy venture fund in several of its strategic investments in oncology companies
- A large pharmaceutical company in several of its equity investments in connection with collaboration and licensing arrangements
- A company focused on longevity in its Series A and Series B Preferred Stock financings that raised over $2 billion
- A company focused on severe immune-mediated diseases in its Series A Preferred Stock and Series A Preferred Stock extension financings that raised over $125 million
- A company focused on transforming oncology clinical trials in its Seed Preferred Stock financing that raised $23 million
- A company focused on neuroscience in its Series A, Series A-1 and Series B financings that raised over $125 million
- A company focused on complement biology in its Series A and Series B financings that raised over $100 million
M&A and Collaboration and Licensing Transactions*
- A large medical device company in connection with its buy-to-buy transaction in surgical robotics with Revival Healthcare, a private equity fund
- A pharmaceutical company in its research and collaboration license agreements with Alloy Therapeutics to develop a proprietary induced pluripotent stem cell derived CAR-T cell platform and iPSC-derived CAR-NK platform
- A venture capital fund in its up to $110 million collaboration with the Cystic Fibrosis foundation to accelerate the development of genetic therapies for CF
- A private company focused on neuroscience in its collaboration and option to acquire with Merck
- A private company focused on complement biology in its collaboration and option to acquire with Horizon
- A private company in connection with a spinout and acquisition by Merck
- A private company focused on gene therapy in ophthalmology connection with a spinout and acquisition by Novartis
- An Italian company in its sale of shares to a private US company
- A private company in the imaging space in connection with a spinout and acquisition by Lantheus Holdings Inc.
Public Offerings*
- A hedge fund in connection with several PIPE and registered direct offerings
- Initial public offering and follow-on offerings for a company focused on targeting the precursors or growth factors
- Initial public offering and follow-on offerings for a company focused on developing treatments based on the microbiome
- Initial public offering and follow-on offerings for a company focused on developing treatments for NASH and Long COVID
- An operating company in the ophthalmology space in connection with its deSPAC transaction
- A SPAC in its deSPAC with a next-generation of radiopharmaceuticals company
- A SPAC in its deSPAC transaction with a regenerative medicine company
* Represents transactions completed prior to joining Morse.
Outside the Office
Outside the office Laurie likes to spend time with her son and husband, especially while cheering on Boston’s sports teams. Laurie is also an avid yoga practitioner and enjoys working on jigsaw puzzles.
